Dynamic Entry! F.D.A Grants Full Approval to Pfizer-BioNTech Covid Vaccine

| Career Insights

Dynamic Entry! F.D.A Grants Full Approval to Pfizer-BioNTech Covid Vaccine

What just happened?

The Food and Drug Administration (FDA) has granted full approval of the Pfizer vaccine. Subsequently, the vaccine has shown enough effectiveness and safety data to meet the stringent biologics license application requirements.

What does this mean?

Without completing the high-quality reviews and evaluations that Americans expect from the FDA's Centre for Biologic Evaluation and Research, vaccine approvals would undermine the agency. Dr. Peter Marks, director of the FDA Centre, pointed out that of the three COVID-19 vaccines currently available in the United States that meet the criteria for emergency approval, only the Pfizer vaccines are approved for people under 12 years old.

For example, a Juni Kaiser Family Foundation survey found that three in ten unvaccinated adults were more likely to get a vaccine if one of the vaccines was approved by the Food and Drug Administration. Vaccine manufacturers can apply for emergency approval because it takes less time than is necessary for full approval. The safety and efficacy of the vaccine have been tested in extensive studies that have confirmed that millions of doses have been administered since the vaccine launch last year. One hope is that full approval will convince those who oppose or are hesitant to vaccinate that the vaccine is safe.

Prior to this, there was pressure mounting on the Food and Drug Administration to formally approve Pfizer's COVID-19 vaccine,with doctors and health experts across the country saying that it is unclear what impact such approval would have on patients and providers. Scientists and doctors fear that the hesitation in vaccination is driven by the fact that vaccines currently available in the United States are manufactured by Johnson's Johnson (Johnson'J) and Pfizer, Biotech (Dagens) that were approved and then approved in emergencies. According to Dr. Paul Offit, a prominent member of the CDC's vaccine advisory committee and director of the Vaccine Education Center at the Children's Hospital of Philadelphia, the FDA is working "around the clock" to approve the vaccine.

In a joint statement, the food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) said that Americans who have already been vaccinated would not need to take COVID-19 booster shots at this time. President Joe Biden said last week that he expected the vaccine to be approved in early autumn, but the FDA did not comment on a timeline. The European Medicines Agency (EMA) said it was too early to determine if more than two vaccinations would be needed but said it was confident the established scheme was sufficient. For emergency approval, the FDA requires that at least half of the participants in the original study be monitored for at least two months after vaccination.

How does it impact the legal sector?

The CDC has been tracking real-world data on vaccines since more than 165 million people were vaccinated in the United States against COVID-19. The FDA is aware of much of the data, for example, on rare side effects caused by vaccines from J & J and Pfizer that have not appeared in clinical trials. This is because the vast majority of vaccine-related side effects occur after vaccination.

Pfizer said it would file a "rolling application" in May, while Moderna, which makes one of the other approved COVID-19 vaccines, said it would file a "rolling application" in June, meaning companies can submit portions of their applications and continue to collect data.

AstraZeneca said it intends to seek emergency approval after the Wall Street Journal reported that the company had run into trouble with collecting data for its FDA request for emergency use of its COVID-19 vaccine, despite millions of people having already been vaccinated in the U.S. federal agencies when the company filed its request on May 7.

The U.S. Food and Drug Administration has granted emergency use authorization (EUA) for a COVID-19 vaccine developed by Pfizer and Biotech after months of intense anticipation, the first US-approved vaccine. The FDA had begun to accelerate the approval process for Pfizer / Biotech Covid-19 vaccines in response to pressure to provide additional resources, believing that a lack of full approval would hamper efforts to get more Americans vaccinated. Pfizer Inc. (Pfizer) and BioNTech S.E. (BioNTech S.E.) announced today that the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and ‘ Prevention (CDC) has today recommended the use of human papillomavirus (HPV) vaccine developed by Pfizer for people aged 16 and over in the context of an FDA-issued emergency approval (EEA).

According to the Wall Street Journal, AstraZeneca has passed its FDA request for urgent use of its COVID-19 vaccine and is now seeking full approval, citing people familiar with the process. Full authorisation means that anyone can be vaccinated, and additional vaccine boosters can be authorised. Withdrawing the submission would allow the vaccine to be approved for younger groups as more data becomes available.

Pfizer Biotech is the only vaccine approved for emergency use for adolescents between 12 and 17 years after Moderna last month applied for such approval. Emergency approval streamlines the regulatory process so that the vaccine can be made available to the public without following the strict procedure required by the FDA to ensure the safety and efficacy of the vaccines. This means the vaccine will be approved for use by Pfizer for people under 16 and Moderna for those under 18.

There are many concerns about its potential legal impact, especially on liability. The most significant being whether there is a need to change current laws, as the covid vaccine may impact any current product liability rules or regulations. Further to this, it may impact future product liability cases related to this vaccine if more information comes to light about side effects from the vaccine. What further needs to be considered here is how individual US states will all and regulate the vaccine within their borders.





Stay Tuned

Receive regular news, updates, upcoming events and more...